Imfinzi™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

Listen to the audio transcription of the CMI leaflet.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Non-small cell lung cancer (NSCLC), IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours equal to or greater than 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements., IMFINZI is indicated for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy (CRT).,Small cell lung cancer (SCLC), IMFINZI as monotherapy is indicated for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT)., IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).,Biliary tract cancer (BTC),IMFINZI in combination with gemcitabine and cisplatin is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).,Hepatocellular carcinoma (HCC),IMFINZI in combination with tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD- 1/PD-L1 inhibitor.,Endometrial cancer,IMFINZI in combination with carboplatin and paclitaxel, followed by IMFINZI monotherapy, is indicated for the first-line treatment of patients with primary advanced or recurrent endometrial cancer.,Bladder cancer,IMFINZI in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, is indicated for the treatment of adults with muscle invasive bladder cancer (MIBC).,Gastric and gastroesophageal junction (GOJ) cancer (GC/GOJC),IMFINZI in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, is indicated for the treatment of adults with resectable gastric or gastroesophageal junction adenocarcinoma.

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, concentrated
• Intravenous Infusion
• 2.4mL concentrated solution in 10mL Type1 glass vial with elastomeric stopper and a grey flip-off aluminum seal containing 120 mg durvalumab.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:

• 13745K (Opens in new tab)
• 13779F (Opens in new tab)
• 11911X (Opens in new tab)
• 13775B (Opens in new tab)
• 13767N (Opens in new tab)
• 13766M (Opens in new tab)
• 13780G (Opens in new tab)
• 11915D (Opens in new tab)
• 14889P (Opens in new tab)
• 14925M (Opens in new tab)
• 14932X (Opens in new tab)
• 14942K (Opens in new tab)
• 15068C (Opens in new tab)
• 15091G (Opens in new tab)
• 15283J (Opens in new tab)
• 15292W (Opens in new tab)
• 15324M (Opens in new tab)
• 15330W (Opens in new tab)

Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Durvalumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).